
Pharmacally
PCSK9
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in PCSK9
Clinical TrialsMerck’s Oral PCSK9 Candidate Enlicitide Cuts LDL-C by 64.6% in Phase 3 Add-On StudyEnlicitide, Merck’s investigational oral PCSK9 inhibitor, significantly reduced LDL cholesterol and outperformed standard oral non-statin therapies in the Phase 3 CORALreef AddOn study, reinforcing its potential as a…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.